 Cindy Stowe
Concepts (192)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 11 | 2023 | 165 | 2.690 |
Why?
| | Students, Pharmacy | 9 | 2019 | 147 | 2.020 |
Why?
| | Educational Measurement | 6 | 2019 | 232 | 1.290 |
Why?
| | Alprostadil | 2 | 2011 | 12 | 0.780 |
Why?
| | Constipation | 2 | 2011 | 34 | 0.760 |
Why?
| | Cystic Fibrosis | 3 | 2011 | 157 | 0.680 |
Why?
| | Cooperative Behavior | 1 | 2020 | 253 | 0.640 |
Why?
| | Program Evaluation | 3 | 2016 | 379 | 0.590 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 184 | 0.580 |
Why?
| | Coronavirus Infections | 1 | 2020 | 192 | 0.570 |
Why?
| | Curriculum | 8 | 2023 | 434 | 0.530 |
Why?
| | Thinking | 1 | 2014 | 21 | 0.510 |
Why?
| | Pharmacists | 1 | 2016 | 152 | 0.500 |
Why?
| | Education, Medical, Undergraduate | 2 | 2008 | 84 | 0.500 |
Why?
| | Personal Satisfaction | 2 | 2014 | 90 | 0.490 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 541 | 0.470 |
Why?
| | Pharmaceutical Services | 2 | 2023 | 57 | 0.440 |
Why?
| | Health Surveys | 1 | 2014 | 261 | 0.440 |
Why?
| | Pharmacy | 2 | 2023 | 64 | 0.420 |
Why?
| | Chlorides | 2 | 2008 | 58 | 0.370 |
Why?
| | Faculty | 3 | 2016 | 84 | 0.370 |
Why?
| | Anticonvulsants | 2 | 2000 | 129 | 0.340 |
Why?
| | Cesium | 1 | 2008 | 8 | 0.330 |
Why?
| | Problem-Based Learning | 1 | 2008 | 48 | 0.320 |
Why?
| | Humans | 35 | 2023 | 54391 | 0.310 |
Why?
| | Quality of Life | 1 | 2014 | 924 | 0.300 |
Why?
| | Electrocardiography | 1 | 2008 | 290 | 0.280 |
Why?
| | Students, Medical | 1 | 2008 | 178 | 0.270 |
Why?
| | Drugs, Generic | 1 | 2004 | 6 | 0.250 |
Why?
| | Omeprazole | 1 | 2004 | 17 | 0.250 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 20 | 0.250 |
Why?
| | Health Benefit Plans, Employee | 1 | 2004 | 17 | 0.250 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2004 | 24 | 0.250 |
Why?
| | Nonprescription Drugs | 1 | 2004 | 42 | 0.250 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 109 | 0.240 |
Why?
| | Blood Pressure | 2 | 2008 | 587 | 0.240 |
Why?
| | Proton Pump Inhibitors | 1 | 2004 | 84 | 0.240 |
Why?
| | Schools, Pharmacy | 4 | 2023 | 68 | 0.230 |
Why?
| | Pharmacies | 1 | 2023 | 63 | 0.220 |
Why?
| | Amphetamines | 1 | 2002 | 28 | 0.220 |
Why?
| | Administrative Personnel | 1 | 2002 | 16 | 0.210 |
Why?
| | Methylphenidate | 1 | 2002 | 94 | 0.200 |
Why?
| | Phenytoin | 1 | 2000 | 23 | 0.200 |
Why?
| | Chloride Channels | 2 | 2011 | 29 | 0.200 |
Why?
| | Academic Medical Centers | 1 | 2002 | 146 | 0.190 |
Why?
| | Heart Rate | 1 | 2002 | 358 | 0.190 |
Why?
| | Young Adult | 5 | 2016 | 4318 | 0.190 |
Why?
| | Organizational Culture | 1 | 2020 | 46 | 0.180 |
Why?
| | Empathy | 1 | 2020 | 48 | 0.180 |
Why?
| | Confusion | 1 | 2000 | 20 | 0.180 |
Why?
| | Fructose | 1 | 2000 | 29 | 0.180 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 231 | 0.180 |
Why?
| | Acidosis | 1 | 2000 | 38 | 0.180 |
Why?
| | Patient Care Team | 1 | 2002 | 273 | 0.180 |
Why?
| | Education, Distance | 1 | 2020 | 39 | 0.180 |
Why?
| | Pilot Projects | 4 | 2011 | 807 | 0.180 |
Why?
| | Theophylline | 1 | 1999 | 24 | 0.170 |
Why?
| | Central Nervous System Stimulants | 1 | 2002 | 255 | 0.170 |
Why?
| | Male | 17 | 2016 | 27347 | 0.170 |
Why?
| | Leadership | 1 | 2020 | 114 | 0.170 |
Why?
| | Antitubercular Agents | 1 | 1999 | 90 | 0.170 |
Why?
| | Self Care | 1 | 2020 | 147 | 0.170 |
Why?
| | Brain Injuries | 1 | 2000 | 184 | 0.170 |
Why?
| | Tuberculosis | 1 | 1999 | 104 | 0.170 |
Why?
| | Vasodilator Agents | 1 | 1999 | 111 | 0.160 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 390 | 0.160 |
Why?
| | Communication | 1 | 2020 | 265 | 0.160 |
Why?
| | Down Syndrome | 1 | 1999 | 100 | 0.160 |
Why?
| | Female | 14 | 2016 | 28471 | 0.160 |
Why?
| | Teaching | 2 | 2019 | 125 | 0.150 |
Why?
| | Infusion Pumps | 1 | 1996 | 13 | 0.150 |
Why?
| | Dobutamine | 1 | 1996 | 24 | 0.150 |
Why?
| | Histamine H2 Antagonists | 3 | 2003 | 23 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2016 | 19 | 0.140 |
Why?
| | Adult | 7 | 2016 | 14207 | 0.140 |
Why?
| | Cardiotonic Agents | 1 | 1996 | 95 | 0.140 |
Why?
| | Dopamine | 1 | 1996 | 190 | 0.130 |
Why?
| | Hemodynamics | 1 | 1996 | 291 | 0.130 |
Why?
| | Psychometrics | 1 | 2016 | 239 | 0.130 |
Why?
| | Pandemics | 1 | 2020 | 594 | 0.130 |
Why?
| | Triazoles | 2 | 2005 | 119 | 0.120 |
Why?
| | Competency-Based Education | 2 | 2023 | 22 | 0.120 |
Why?
| | Helping Behavior | 1 | 2013 | 11 | 0.110 |
Why?
| | Naloxone | 1 | 1993 | 61 | 0.110 |
Why?
| | Pyrimidines | 2 | 2005 | 196 | 0.110 |
Why?
| | Attitude | 1 | 2013 | 81 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1301 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 1696 | 0.100 |
Why?
| | Antifungal Agents | 2 | 2005 | 363 | 0.100 |
Why?
| | Famotidine | 2 | 2003 | 11 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2016 | 6459 | 0.090 |
Why?
| | Liver Regeneration | 1 | 2010 | 57 | 0.090 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 35 | 0.090 |
Why?
| | Secondary Prevention | 1 | 2010 | 89 | 0.090 |
Why?
| | Intestinal Obstruction | 1 | 2010 | 37 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2011 | 5612 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 232 | 0.080 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2010 | 140 | 0.080 |
Why?
| | Biphenyl Compounds | 1 | 2008 | 30 | 0.080 |
Why?
| | Hepatocytes | 1 | 2010 | 214 | 0.080 |
Why?
| | Alzheimer Disease | 1 | 1993 | 369 | 0.080 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 46 | 0.080 |
Why?
| | Tetrazoles | 1 | 2008 | 43 | 0.080 |
Why?
| | Self-Assessment | 1 | 2008 | 50 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2008 | 54 | 0.080 |
Why?
| | Peer Group | 1 | 2008 | 58 | 0.080 |
Why?
| | Antitussive Agents | 1 | 2007 | 9 | 0.080 |
Why?
| | Dextromethorphan | 1 | 2007 | 20 | 0.070 |
Why?
| | Program Development | 1 | 2008 | 198 | 0.070 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2008 | 40 | 0.070 |
Why?
| | Child | 5 | 2008 | 7368 | 0.070 |
Why?
| | Infant | 6 | 2007 | 3829 | 0.070 |
Why?
| | Acetaminophen | 1 | 2010 | 350 | 0.070 |
Why?
| | Peritoneal Dialysis, Continuous Ambulatory | 1 | 2006 | 7 | 0.070 |
Why?
| | Ceftazidime | 1 | 2006 | 9 | 0.070 |
Why?
| | Peritonitis | 1 | 2006 | 33 | 0.070 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2008 | 203 | 0.070 |
Why?
| | Amphotericin B | 1 | 2005 | 122 | 0.060 |
Why?
| | Clinical Competence | 1 | 2008 | 444 | 0.060 |
Why?
| | Adolescent | 5 | 2008 | 6900 | 0.060 |
Why?
| | Candidiasis | 1 | 2005 | 122 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2008 | 352 | 0.060 |
Why?
| | Trichosporon | 1 | 2003 | 14 | 0.060 |
Why?
| | Liver | 1 | 2010 | 1226 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1476 | 0.060 |
Why?
| | Hypertension | 1 | 2008 | 565 | 0.060 |
Why?
| | Mycoses | 1 | 2003 | 162 | 0.050 |
Why?
| | Metabolic Clearance Rate | 2 | 1999 | 75 | 0.050 |
Why?
| | Models, Educational | 1 | 2002 | 35 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2005 | 231 | 0.050 |
Why?
| | Databases, Factual | 1 | 2004 | 683 | 0.050 |
Why?
| | United States | 2 | 2023 | 5208 | 0.050 |
Why?
| | Aging | 1 | 2007 | 784 | 0.050 |
Why?
| | Sleep | 1 | 2002 | 188 | 0.050 |
Why?
| | Infant, Newborn | 4 | 2007 | 2923 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 232 | 0.050 |
Why?
| | Ranitidine | 1 | 1999 | 5 | 0.050 |
Why?
| | Copper Sulfate | 1 | 1999 | 3 | 0.050 |
Why?
| | Burns, Chemical | 1 | 1999 | 9 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2006 | 825 | 0.040 |
Why?
| | North America | 1 | 1999 | 70 | 0.040 |
Why?
| | Gastric Mucosa | 1 | 1999 | 59 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 383 | 0.040 |
Why?
| | Feedback | 1 | 2019 | 61 | 0.040 |
Why?
| | Stomach | 1 | 1999 | 81 | 0.040 |
Why?
| | Acute Disease | 1 | 2000 | 403 | 0.040 |
Why?
| | Protein Binding | 1 | 2000 | 736 | 0.040 |
Why?
| | Arkansas | 1 | 2004 | 2100 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2019 | 314 | 0.040 |
Why?
| | Seizures | 1 | 2000 | 209 | 0.040 |
Why?
| | Child, Preschool | 3 | 2003 | 4158 | 0.040 |
Why?
| | College Admission Test | 1 | 2016 | 16 | 0.040 |
Why?
| | School Admission Criteria | 1 | 2016 | 37 | 0.030 |
Why?
| | Ego | 1 | 2013 | 8 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 991 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2013 | 115 | 0.030 |
Why?
| | Focus Groups | 1 | 2013 | 207 | 0.030 |
Why?
| | Universities | 1 | 2013 | 164 | 0.030 |
Why?
| | Perception | 1 | 2013 | 142 | 0.030 |
Why?
| | Educational Status | 1 | 2013 | 261 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2013 | 643 | 0.020 |
Why?
| | Health Status | 1 | 2013 | 368 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 1996 | 608 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 134 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 199 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 208 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 570 | 0.020 |
Why?
| | Dealkylation | 1 | 2007 | 5 | 0.020 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2007 | 25 | 0.020 |
Why?
| | Biotransformation | 1 | 2007 | 100 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1090 | 0.020 |
Why?
| | Cytokines | 1 | 2010 | 677 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 3210 | 0.020 |
Why?
| | Hemodialysis Solutions | 1 | 2006 | 4 | 0.020 |
Why?
| | Alleles | 1 | 2007 | 277 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2007 | 192 | 0.020 |
Why?
| | Animals | 2 | 2010 | 14409 | 0.020 |
Why?
| | Genotype | 1 | 2007 | 600 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2010 | 1647 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2003 | 225 | 0.010 |
Why?
| | Neutropenia | 1 | 2003 | 120 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2003 | 178 | 0.010 |
Why?
| | Infant, Premature | 1 | 2005 | 337 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 13082 | 0.010 |
Why?
| | Poisoning | 1 | 1999 | 31 | 0.010 |
Why?
| | Endoscopy, Digestive System | 1 | 1999 | 53 | 0.010 |
Why?
| | Gastroesophageal Reflux | 1 | 1999 | 49 | 0.010 |
Why?
| | Prospective Studies | 1 | 2006 | 2606 | 0.010 |
Why?
| | Gastric Acidity Determination | 1 | 1998 | 11 | 0.010 |
Why?
| | Linear Models | 1 | 1999 | 308 | 0.010 |
Why?
| | Mice | 1 | 2010 | 6428 | 0.010 |
Why?
| | Administration, Oral | 1 | 1999 | 461 | 0.010 |
Why?
|
|
Stowe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|